We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+23.06%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$849M
AUM Growth
-$105M
Cap. Flow
-$227M
Cap. Flow %
-26.79%
Top 10 Hldgs %
85.18%
Holding
28
New
4
Increased
5
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$53.2M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$43.8M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$21M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$17M
5
PACB icon
Pacific Biosciences
PACB
+$15.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$91.9M
2
UTHR icon
United Therapeutics
UTHR
+$86.9M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$69.5M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$48.3M
5
PCRX icon
Pacira BioSciences
PCRX
+$44.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
26
DELISTED
Array Biopharma Inc
ARRY
– –
-1,373,471
Closed -$12.3M
HZNP
27
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-6,218,903
Closed -$91.9M
NVDQ
28
DELISTED
Novadaq Technologies Inc.
NVDQ
– –
-3,018,179
Closed -$23.5M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Consonance Capital Management held 28 positions worth $849M, down 11% from $954M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Consonance Capital Management withdrew a net $227M in Q2 2017, closing 8 positions and reducing 7 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $91.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in PTC Therapeutics worth $72.3M.

  • Consonance Capital Management's largest Q2 2017 buy was PTC Therapeutics: 3,946,009 shares worth $72.3M.
  • Consonance Capital Management added most to Advanced Accelerator Applications S.A. in Q2 2017, an estimated $21M increase.
  • Consonance Capital Management's biggest Q2 2017 reduction was Clovis Oncology, Inc., cutting an estimated $48.3M.
  • Consonance Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017, selling an estimated $91.9M.
  • Consonance Capital Management's ten largest holdings make up 85% of its $849M portfolio in Q2 2017.
  • Consonance Capital Management opened 4 new positions and closed 8 in Q2 2017.
  • Consonance Capital Management's portfolio value fell 11% quarter-over-quarter to $849M.

Based on Consonance Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.